[go: up one dir, main page]

MX2021003867A - Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado. - Google Patents

Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado.

Info

Publication number
MX2021003867A
MX2021003867A MX2021003867A MX2021003867A MX2021003867A MX 2021003867 A MX2021003867 A MX 2021003867A MX 2021003867 A MX2021003867 A MX 2021003867A MX 2021003867 A MX2021003867 A MX 2021003867A MX 2021003867 A MX2021003867 A MX 2021003867A
Authority
MX
Mexico
Prior art keywords
truncated
monoclonal antibody
humanized anti
beta monoclonal
amiloid
Prior art date
Application number
MX2021003867A
Other languages
English (en)
Inventor
Thomas Bayer
Preeti Bakrania
Sarah Davies
Alex Brown
Chido Mpamhanga
David Matthews
Mark Carr
Gareth Hall
Original Assignee
Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin filed Critical Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin
Publication of MX2021003867A publication Critical patent/MX2021003867A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a anticuerpos humanizados que se unen a péptidos amiloides, cuyos anticuerpos comprenden mutaciones en los dominios variables de cadena pesada y/o cadena ligera, cuyas mutaciones mejoran la actividad de unión; los anticuerpos pueden ser útiles en el tratamiento de la enfermedad de Alzheimer (AD).
MX2021003867A 2018-10-04 2019-10-02 Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado. MX2021003867A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201816210 2018-10-04
PCT/EP2019/076772 WO2020070225A1 (en) 2018-10-04 2019-10-02 Humanised anti-n-truncated amyloid beta monoclonal antibody

Publications (1)

Publication Number Publication Date
MX2021003867A true MX2021003867A (es) 2021-09-08

Family

ID=68136417

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003867A MX2021003867A (es) 2018-10-04 2019-10-02 Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado.

Country Status (13)

Country Link
US (1) US20230203140A9 (es)
EP (1) EP3861023A1 (es)
JP (1) JP7610515B2 (es)
KR (1) KR20210080400A (es)
CN (1) CN113056480A (es)
AU (1) AU2019354714A1 (es)
BR (1) BR112021006153A2 (es)
CA (1) CA3114669A1 (es)
EA (1) EA202190954A1 (es)
IL (1) IL281979A (es)
MX (1) MX2021003867A (es)
SG (1) SG11202102765RA (es)
WO (1) WO2020070225A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CA3167073A1 (en) 2020-03-10 2021-09-16 Preeti BAKRANIA Cyclic peptides
WO2024133925A1 (en) 2022-12-22 2024-06-27 Bioarctic Ab Antibody which binds to abetape3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474900A (en) 1892-05-17 William byrnes
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
KR101735257B1 (ko) * 2007-01-05 2017-05-12 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
WO2013167681A1 (en) * 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS
WO2015173133A1 (en) * 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
IL256579B2 (en) * 2015-07-16 2023-03-01 Probiodrug Ag Human antibodies
CN111518206B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CA3167073A1 (en) * 2020-03-10 2021-09-16 Preeti BAKRANIA Cyclic peptides

Also Published As

Publication number Publication date
JP7610515B2 (ja) 2025-01-08
CA3114669A1 (en) 2020-04-09
US20210347867A1 (en) 2021-11-11
JP2022513331A (ja) 2022-02-07
KR20210080400A (ko) 2021-06-30
WO2020070225A1 (en) 2020-04-09
BR112021006153A2 (pt) 2021-06-29
IL281979A (en) 2021-05-31
SG11202102765RA (en) 2021-04-29
AU2019354714A1 (en) 2021-04-29
CN113056480A (zh) 2021-06-29
US20230203140A9 (en) 2023-06-29
EA202190954A1 (ru) 2021-06-29
EP3861023A1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA201891909A1 (ru) TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MX2023001726A (es) Anticuerpos anti-c5 y usos de los mismos.
EA202092847A1 (ru) Антитела к cd3 и их применение
EA201992163A1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ
EA201792657A1 (ru) Связывающие lag-3 молекулы и способы их применения
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
PE20210186A1 (es) Anticuerpos anti-sortilina y metodos para su uso
MX2021003867A (es) Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado.
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA202092420A1 (ru) Антитело против pd-l1 и его применение
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
EA201990895A1 (ru) Антитела к о1 и варианты их применения
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
PH12021552148A1 (en) Cd3 binding molecules
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
EA201892427A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИ-FcRn АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ
MX2020008768A (es) Agentes anticuerpos anti-cd25.
EA201891800A1 (ru) Антитела к цитруллинированным hla-полипептидам и их применение